SGLT2 inhibitors

Biochemical Pharmacology

Volumn 101, Issue , 2016, Pages 27-39

  Dardi, I ^a   Kouvatsos, T ^a   Jabbour, S A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN; INSULIN; LINAGLIPTIN; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; ANTIDIABETIC AGENT; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ABNORMAL LABORATORY RESULT; ADD ON THERAPY; ANTIDIABETIC ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CANCER RISK; DIABETIC PATIENT; DOSE RESPONSE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FRACTURE; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION; GLUCONEOGENESIS; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE UTILIZATION; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; KIDNEY PROXIMAL TUBULE; META ANALYSIS; MODERATE RENAL IMPAIRMENT; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSMOTIC DIURESIS; PANCREAS ISLET BETA CELL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SYSTEMATIC REVIEW; URINARY EXCRETION; URINARY TRACT INFECTION; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; KIDNEY TUBULE ABSORPTION; METABOLISM; NEPHRON; PATHOPHYSIOLOGY;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MEMBRANE TRANSPORT MODULATORS; MODELS, BIOLOGICAL; NEPHRONS; RENAL REABSORPTION; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84957431946     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2015.09.005     Document Type: Note

References (79)

1. M.Y. Leung, L.M. Pollack, G.A. Colditz, and S.H. Chang Life years lost and lifetime health care expenditures associated with diabetes in the U.S., national health interview survey, 1997-2000 Diabetes Care 38 3 2015 460 468
2. L. Guariguata, D.R. Whiting, I. Hambleton, J. Beagley, U. Linnenkamp, and J.E. Shaw Global estimates of diabetes prevalence for 2013 and projections for 2035 Diabetes Res. Clin. Pract. 103 2 2014 137 149
3. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck, and et al. Management of hyperglycemia in type 2 diabetes, a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 38 1 2015 140 149
4. S.A. Jabbour SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem Postgrad. Med. 126 1 2014 111 117
5. J.R. White Sodium glucose cotransporter 2 inhibitors Med. Clin. North Am. 99 1 2015 131 143
6. Y. Handelsman, Z.T. Bloomgarden, G. Grunberger, G. Umpierrez, R.S. Zimmerman, T.S. Bailey, and et al. American association of clinical endocrinologists and American college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015 Endocr. Pract. 21 2015 1 87
7. S.A. Jabbour, and B.J. Goldstein Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes Int. J. Clin. Pract. 62 8 2008 1279 1284
8. L.A. Gallo, E.M. Wright, and V. Vallon Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences Diab. Vasc. Dis. Res. 12 2 2015 78 89
9. R. Lajara The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus Expert Opin. Pharmacother. 15 17 2014 2565 2585
10. J.E. Gerich Physiology of glucose homeostasis Diabetes Obes. Metab. 2 6 2000 345 350
11. A. Mather, and C. Pollock Glucose handling by the kidney Kidney Int. Suppl. 120 2011 S1 S6
12. J.E. Gerich Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications Diabet. Med. 27 2 2010 136 142
13. C. Meyer, J.M. Dostou, S.L. Welle, and J.E. Gerich Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis Am. J. Physiol. Endocrinol. Metab. 282 2 2002 E419 E427
14. C. Meyer, M. Stumvoll, V. Nadkarni, J. Dostou, A. Mitrakou, and J. Gerich Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus J. Clin. Invest. 102 3 1998 619 624
15. J.R. Ehrenkranz, N.G. Lewis, C.R. Kahn, and Roth J. Phlorizin a review Diabetes Metab. Res. Rev. 21 1 2005 31 38
16. M.A. Abdul-ghani, L. Norton, and R.A. Defronzo Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes Endocr. Rev. 32 4 2011 515 531
17. G. Vlotides, and P.R. Mertens Sodium-glucose cotransport inhibitors: mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease Nephrol. Dial. Transplant. 2014
18. S. Nair, and J.P. Wilding Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus J. Clin. Endocrinol. Metab. 95 1 2010 34 42
19. E.M. Wright, D.D. Loo, and B.A. Hirayama Biology of human sodium glucose transporters Physiol. Rev. 91 2 2011 733 794
20. R.A. Defronzo, J.A. Davidson, and S. Del Prato The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia Diabetes Obes. Metab. 14 1 2012 5 14
21. H. Rahmoune, P.W. Thompson, J.M. Ward, C.D. Smith, G. Hong, and J. Brown Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes Diabetes 54 12 2005 3427 3434
22. T.C. Hardman, and S.W. Dubrey Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes Diabetes Ther. 2 3 2011 133 145
23. C. Meyer, H.J. Woerle, J.M. Dostou, S.L. Welle, and J.E. Gerich Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes Am. J. Physiol. Endocrinol. Metab. 287 6 2004 E1049 E1056
24. E.M. Vivian Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents Drugs Context 3 2014 212264
25. S.J. Farber, E.Y. Berger, and D.P. Earle Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose J. Clin. Invest. 30 2 1951 125 129
26. Y. Lu, S.C. Griffen, D.W. Boulton, and T.A. Leil Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans Front. Pharmacol. 5 2014 274
27. J.J. Liu, T. Lee, and R.A. Defronzo Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 61 9 2012 2199 2204
28. V. Vallon The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus Annu. Rev. Med. 66 2015 255 270
29. X.P. Yang, D. Lai, X.Y. Zhong, H.P. Shen, and Y.L. Huang Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis Eur. J. Clin. Pharmacol. 70 Octobet (10) 2014 1149 1158
30. INVOKANA™ (canagliflozin) tablets, for oral use [package insert]. Janssen Pharmaceuticals, Titusville, NJ; 2014.
31. L.E. Nicolle, G. Capuano, K. Ways, and K. Usiskin Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study Curr. Med. Res. Opin. 28 2012 1167 1171
32. N. Mikhail Safety of canagliflozin in patients with type 2 diabetes Curr. Drug Saf. 9 2 2014 127 132
33. L.E. Nicolle, G. Capuano, A. Fung, and K. Usiskin Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor Postgrad. Med. 126 2014 7 17
34. L.K. Elmore, S. Baggett, J.A. Kyle, and J.W. Skelley A review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetes Consult. Pharm. 29 2014 335 346
35. A. Sinclair, B. Bode, S. Harris, U. Vijapurkar, C. Mayer, A. Fung, and et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies BMC Endocr. Disord. 14 2014 37
36. Committee for Medicinal Products for Human Use European Public Assessment Report (EPAR) Canagliflozin European Medicines Agency 2013. EMA/374133/2013.
37. L.A. Leiter, K.-H. Yoon, P. Arias, G. Langslet, J. Xie, D.A. Balis, and et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study Diabetes Care 38 March (3) 2015 355 364
38. B. Bode, K. Stenlöf, S. Harris, D. Sullivan, A. Fung, K. Usiskin, and et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes Diabetes Obes. Metab. 17 March (3) 2015 294 303
39. B. Neal, V. Perkovic, Z. de, D. eeuw, K.W. Mahaffey, G. Fulcher, P. Stein, and et al. Rationale, design, and baseline characteristics of the CANagliflozin cardioVascular assessment study (CANVAS) - a randomized placebo-controlled trial Am. Heart J. 166 2013 217 223.e11
40. B.E. Haas, N.P. ckstien, V.M. feifer, and P. ayer Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin Nutr. Diabetes 4 November (11) 2014 e143
41. K. Stenlöf, W.T. Cefalu, K.A. Kim, M. Alba, K. Usiskin, C. Tong, and et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise Diabetes Obes. Metab. 15 4 2013 372 382
42. N. Inagaki, K. Kondo, T. Yoshinari, N. Takahashi, Y. Susuta, and H. Kuki Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled. Phase III study Expert Opin. Pharmacother. 15 11 2014 1501 1515
43. J. Rosenstock, N. Aggarwal, D. Polidori, Y. Zhao, D. Arbit, K. Usiskin, and et al. Effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes Diabetes Care 35 June (6) 2012 1232 1238
44. J.P. Wilding, G. Charpentier, P. Hollander, G. González-Gálvez, C. Mathieu, F. Vercruysse, and et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitusinadequately controlled with metformin and sulphonylurea: a randomised trial Int. J. Clin. Pract. 67 12 2013 1267 1282
45. T. Forst, R. Guthrie, R. Goldenberg, J. Yee, U. Vijapurkar, G. Meininger, and et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone Diabetes Obes. Metab. 16 5 2014 467 477
46. B. Neal, V. Perkovic, Z. de, D. eeuw, K.W. Mahaffey, G. Fulcher, K. Ways, and et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes Diabetes Care 38 March (3) 2015 403 411 10.2337/dc14-1237
47. W.T. Cefalu, L.A. Leiter, K.H. Yoon, P. Arias, L. Niskanen, J. Xie, and et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 noninferiority trial Lancet 382 9896 2013 941 950
48. L.A. Leiter, K.H. Yoon, P. Arias, G. Langslet, J. Xie, D.A. Balis, and et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study Diabetes Care 38 March (3) 2015 355 364
49. G. Schernthaner, J.L. Gross, J. Rosenstock, M. Guarisco, M. Fu, J. Yee, and et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial Diabetes Care 36 9 2013 2508 2515
50. W.L. Baker, L.R. Smyth, D.M. Riche, E.M. Bourret, K.W. Chamberlin, and W.B. White Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis J. Am. Soc. Hypertens. 8 2014 262 275
51. JARDIANCE™ (empagliflozin) tablets, for oral use [package insert]. Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT; 2014.
52. European Medicines Agency. Assessment report. Jardiance. International non-proprietary name: empagliflozin. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002677/WC500168594.pdf, 2014 (accessed 01.02.15).
53. E. Ferrannini, L. Seman, E. Seewaldt-Becker, S. Hantel, S. Pinnetti, and H.J. Woerle A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes Diabetes Obes. Metab. 15 8 2013 721 728
54. M. Roden, J. Weng, J. Eilbracht, B. Delafont, G. Kim, and H.J. Woerle Empagliflozin monotherapy in drug-naIve patients with type 2 diabetes: a randomised,24-week, double-blind, placebo-controlled, parallel group, trial of SGLT2 Inhibitors in Type 2 Diabetes with sitagliptin as active comparator Lancet Diabetes Endocrinol. 1 3 2013 208 219
55. T. Kadowaki, M. Haneda, N. Inagaki, Y. Terauchi, A. Taniguchi, K. Koiwai, and et al. Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus:a randomized, 12-week, double-blind, placebo-controlled. Phase II trial Adv. Ther. 31 6 2014 621 638
56. J. Rosenstock, L.J. Seman, A. Jelaska, S. Hantel, S. Pinnetti, T. Hach, and et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia Diabetes Obes. Metab. 15 12 2013 1154 1160
57. H.U. Häring, L. Merker, E. Seewaldt-Becker, M. Weimer, T. Meinicke, and U.C. Broedl Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial Diabetes Care 37 6 2014 1650 1659
58. C.S. Kovacs, V. Seshiah, R. Swallow, R. Jones, H. Rattunde, H.J. Woerle, and et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial Diabetes Obes. Metab. 16 2 2014 147 158
59. H.U. Häring, L. Merker, E. Seewaldt-Becker, M. Weimer, T. Meinicke, H.J. Woerle, and et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial Diabetes Care 36 11 2013 3396 3404
60. J. Rosenstock, A. Jelaska, G. Frappin, A. Salsali, G. Kim, H.J. Woerle, and et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes Diabetes Care 37 7 2014 1815 1823
61. A. Liakos, T. Karagiannis, E. Athanasiadou, M. Sarigianni, M. Mainou, K. Papatheodorou, and et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis Diabetes Obes. Metab. 16 10 2014 984 993
62. E. Ferrannini, L. Seman, E. Seewaldt-Becker, S. Hantel, S. Pinnetti, and H.J. Woerle A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes Diabetes Obes. Metab. 15 8 2013 721 728
63. M. Ridderstråle, K.R. Andersen, C. Zeller, G. Kim, H.J. Woerle, U.C. Broedl, and et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active -controlled, double-blind, phase 3 trial Lancet Diabetes Endocrinol. 2 9 2014 691 700
64. A. Lewin, R.A. DeFronzo, S. Patel, D. Liu, R. Kaste, H.J. Woerle, and et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes Diabetes Care 38 3 2015 Mar 394 402
65. R.A. DeFronzo, A. Lewin, S. Patel, D. Liu, R. Kaste, H.J. Woerle, and et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin Diabetes Care 38 March (3) 2015 384 393
66. FARXIGA™ (dapagliflozin) tablets, for oral use [package insert]. Bristol-Myers Squibb Company, Princeton, NJ; 2014.
67. S. Matthaei, K. Bowering, K. Rohwedder, A. Grohl, and S. Parikh Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial Diabetes Care 38 March (3) 2015 365 372
68. J. Rosenstock, L. Hansen, P. Zee, Y. Li, W. Cook, B. Hirshberg, and et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin Diabetes Care 38 March (3) 2015 376 383
69. K.M. Johnsson, A. Ptaszynska, B. Schmitz, J. Sugg, S.J. Parikh, and J.F. List Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin J. Diabetes Complications 27 5 2013 479 484
70. J. Bolinder, Ö. Ljunggren, L. Johansson, J. Wilding, A.M. Langkilde, C.D. Sjöström, and et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin Diabetes Obes. Metab. 16 2 2014 159 169
71. Ö. Ljunggren, J. Bolinder, L. Johansson, J. Wilding, A.M. Langkilde, C.D. Sjöström, and et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin Diabetes Obes. Metab. 14 11 2012 990 999
72. R.R. Henry, J. Rosenstock, S. Edelman, S. Mudaliar, A.G. Chalamandaris, S. Kasichayanula, and et al. Exploring the potential of the sglt2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study Diabetes Care 38 March 2015 412 419
73. Y.N. Sun, Y. Zhou, X. Chen, W.S. Che, and S.W. Leung The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomized controlled trials BMJ Open 4 4 2014 e:004619
74. A.J.P. Scheen, and harmacodynamics efficacy, and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus Drugs 75 2015 33 59
75. J. Bolinder, Ö. Ljunggren, J. Kullberg, L. Johansson, J. Wilding, A.M. Langkilde, and et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin J. Clin. Endocrinol. Metab. 97 3 2012 1020 1031
76. J. Bolinder, Ö. Ljunggren, L. Johansson, J. Wilding, A.M. Langkilde, C.D. Sjöström, and et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin Diabetes Obes. Metab. 16 2 2014 159 169
77. R.F. Rosenwasser, J.N. Rosenwasser, D. Sutton, R. Choksi, and B. Epstein Tofogliflozin: a highly selective SGLT2 inhibitor for the treatment of type 2 diabetes Drugs Today (Barc) 50 November (11) 2014 739 745
78. B. Zambrowicz, Z.M. Ding, I. Ogbaa, K. Frazier, P. Banks, A. Turnage, and et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes Clin. Ther. 35 3 2013 Mar 273 285
79. B. Zambrowicz, J. Freiman, P.M. Brown, K.S. Frazier, A. Turnage, J. Bronner, and et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial Clin. Pharmacol. Ther. 92 August (2) 2012 158 169